Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 17 (June 10), 2008: pp. 2839-2845
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.1829

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eyler, C. E.
Right arrow Articles by Rich, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eyler, C. E.
Right arrow Articles by Rich, J. N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis

Christine E. Eyler, Jeremy N. Rich

From the Departments of Pharmacology and Cancer Biology, Medicine, and Surgery, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham NC

Corresponding author: Jeremy N. Rich, MD, Duke University Medical Center, PO Box 2900, Durham, NC 27710; e-mail: rich0001{at}mc.duke.edu

In an increasing number of cancers, tumor populations called cancer stem cells (CSCs), or tumor-initiating cells, have been defined in functional assays of self-renewal and tumor initiation. Moreover, recent work in several different cancers has suggested the CSC population as a source of chemotherapy and radiation-therapy resistance within tumors. Work in glioblastoma and breast cancers supports the idea that CSCs may possess innate resistance mechanisms against radiation- and chemotherapy-induced cancer cell death, allowing them to survive and initiate tumor recurrence. Several resistance mechanisms have been proposed, including amplified checkpoint activation and DNA damage repair as well as increased Wnt/β-catenin and Notch signaling. Novel targeted therapies against the DNA damage checkpoint or stem-cell maintenance pathways may sensitize CSCs to radiation or other therapies. Another important category of cancer therapies are antiangiogenic and vascular targeting agents, which are also becoming integrated in the treatment paradigm of an increasing number of cancers. Recent results from our laboratory and others support a role for CSCs in the angiogenic drive as well as the mechanism of antiangiogenic agents. Identifying and targeting the molecular mechanisms responsible for CSC therapeutic resistance may improve the efficacy of current cancer therapies.

Supported by the Childhood Brain Tumor Foundation, the Pediatric Brain Tumor Foundation of the United States, Accelerate Brain Cancer Cure, Alexander and Margaret Stewart Trust, Brain Tumor Society, Goldhirsh Foundation, Duke Comprehensive Cancer Center Stem Cell Initiative Grant (J.N.R.), and National Institutes of Health Grants No. NS047409, NS054276, and CA116659 (J.N.R.). J.N.R. is a Damon Runyon-Lilly Clinical Investigator supported by the Damon Runyon Cancer Research Foundation and a Sidney Kimmel Foundation for Cancer Research Scholar. C.E.E. receives Medical Scientist Training Program support from the National Institute of General Medical Sciences (Grant No. 2T32GM007171).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
S. R. Pine, B. M. Ryan, L. Varticovski, A. I. Robles, and C. C. Harris
Microenvironmental modulation of asymmetric cell division in human lung cancer cells
PNAS, February 2, 2010; 107(5): 2195 - 2200.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. Maenhaut, J.E. Dumont, P.P. Roger, and W.C.G. van Staveren
Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis
Carcinogenesis, February 1, 2010; 31(2): 149 - 158.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. E. Brown, R. Starr, C. Martinez, B. Aguilar, M. D'Apuzzo, I. Todorov, C.-C. Shih, B. Badie, M. Hudecek, S. R. Riddell, et al.
Recognition and Killing of Brain Tumor Stem-Like Initiating Cells by CD8+ Cytolytic T Cells
Cancer Res., December 1, 2009; 69(23): 8886 - 8893.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. Monticone, E. Biollo, A. Fabiano, M. Fabbi, A. Daga, F. Romeo, M. Maffei, A. Melotti, W. Giaretti, G. Corte, et al.
z-Leucinyl-Leucinyl-Norleucinal Induces Apoptosis of Human Glioblastoma Tumor-Initiating Cells by Proteasome Inhibition and Mitotic Arrest Response
Mol. Cancer Res., November 1, 2009; 7(11): 1822 - 1834.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
A. M. McCord, M. Jamal, U. T. Shankavarum, F. F. Lang, K. Camphausen, and P. J. Tofilon
Physiologic Oxygen Concentration Enhances the Stem-Like Properties of CD133+ Human Glioblastoma Cells In vitro
Mol. Cancer Res., April 1, 2009; 7(4): 489 - 497.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. A. Ajani, J. G. Izzo, and J.-S. Lee
Chemotherapy and Radiotherapy Resistance: Complexity, Reality, and Promise
J. Clin. Oncol., January 1, 2009; 27(1): 162 - 163.
[Full Text] [PDF]


Home page
Endocr Relat CancerHome page
G. V Shah, S. Thomas, A. Muralidharan, Y. Liu, P. L Hermonat, J. Williams, and J. Chaudhary
Calcitonin promotes in vivo metastasis of prostate cancer cells by altering cell signaling, adhesion, and inflammatory pathways
Endocr. Relat. Cancer, December 1, 2008; 15(4): 953 - 964.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. M. Boman and M. S. Wicha
Cancer Stem Cells: A Step Toward the Cure
J. Clin. Oncol., June 10, 2008; 26(17): 2795 - 2799.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online